ESR1 and endometrial cancer: An in vitro study on endometrial adenocarcinomas demonstrated that a physiological concentration of melatonin at 10− 9 M for 4 h and 96 h incubation showed no inhibition on SNG-II estrogen receptor-negative, endometrial cancer cell growth.